TRIFLUOPERAZINE HYDROCHLORIDE- trifluoperazine hydrochloride tablet, film coated Spojené státy - angličtina - NLM (National Library of Medicine)

trifluoperazine hydrochloride- trifluoperazine hydrochloride tablet, film coated

remedyrepack inc. - trifluoperazine hydrochloride (unii: 6p1y2snf5v) (trifluoperazine - unii:214izi85k3) - for the management of schizophrenia. trifluoperazine hcl is effective for the short-term treatment of generalized non-psychotic anxiety. however, trifluoperazine hcl is not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines). when used in the treatment of non-psychotic anxiety, trifluoperazine hcl should not be administered at doses of more than 6 mg per day or for longer than 12 weeks because the use of trifluoperazine hcl at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings ). the effectiveness of trifluoperazine hcl as a treatment for non-psychotic anxiety was established in a four-week clinical multicenter study of outpatients with generalized anxiety disorder (dsm-iii). this evidence does not predict that trifluoperazine hcl will be useful in patients with other non-psychotic conditions in w

TRIFLUOPERAZINE HYDROCHLORIDE tablet, film coated Spojené státy - angličtina - NLM (National Library of Medicine)

trifluoperazine hydrochloride tablet, film coated

bryant ranch prepack - trifluoperazine hydrochloride (unii: 6p1y2snf5v) (trifluoperazine - unii:214izi85k3) - for the management of schizophrenia. trifluoperazine hcl is effective for the short-term treatment of generalized non-psychotic anxiety. however, trifluoperazine hcl is not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines). when used in the treatment of non-psychotic anxiety, trifluoperazine hcl should not be administered at doses of more than 6 mg per day or for longer than 12 weeks because the use of trifluoperazine hcl at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings ). the effectiveness of trifluoperazine hcl as a treatment for non-psychotic anxiety was established in a four-week clinical multicenter study of outpatients with generalized anxiety disorder (dsm-iii). this evidence does not predict that trifluoperazine hcl will be useful in patients with other non-psychotic conditions in which anxiety, or signs that mimic anxiety, are found (i.e., physical illness, organic mental conditions, agitated depression, character pathologies, etc.). trifluoperazine hcl has not been shown effective in the management of behavioral complications in patients with mental retardation. a known hypersensitivity to phenothiazines, comatose or greatly depressed states due to central nervous system depressants and, in cases of existing blood dyscrasias, bone marrow depression and pre-existing liver damage.

TRIFLUOPERAZINE HYDROCHLORIDE tablet, film coated Spojené státy - angličtina - NLM (National Library of Medicine)

trifluoperazine hydrochloride tablet, film coated

bryant ranch prepack - trifluoperazine hydrochloride (unii: 6p1y2snf5v) (trifluoperazine - unii:214izi85k3) - for the management of schizophrenia. trifluoperazine hcl is effective for the short-term treatment of generalized non-psychotic anxiety. however, trifluoperazine hcl is not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines). when used in the treatment of non-psychotic anxiety, trifluoperazine hcl should not be administered at doses of more than 6 mg per day or for longer than 12 weeks because the use of trifluoperazine hcl at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings ). the effectiveness of trifluoperazine hcl as a treatment for non-psychotic anxiety was established in a four-week clinical multicenter study of outpatients with generalized anxiety disorder (dsm-iii). this evidence does not predict that trifluoperazine hcl will be useful in patients with other non-psychotic conditions in which anxiety, or signs that mimic anxiety, are found (i.e., physical illness, organic mental conditions, agitated depression, character pathologies, etc.). trifluoperazine hcl has not been shown effective in the management of behavioral complications in patients with mental retardation. a known hypersensitivity to phenothiazines, comatose or greatly depressed states due to central nervous system depressants and, in cases of existing blood dyscrasias, bone marrow depression and pre-existing liver damage.

TRIFLUOPERAZINE HYDROCHLORIDE tablet, film coated Spojené státy - angličtina - NLM (National Library of Medicine)

trifluoperazine hydrochloride tablet, film coated

bryant ranch prepack - trifluoperazine hydrochloride (unii: 6p1y2snf5v) (trifluoperazine - unii:214izi85k3) - for the management of schizophrenia. trifluoperazine hcl is effective for the short-term treatment of generalized non-psychotic anxiety. however, trifluoperazine hcl is not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines). when used in the treatment of non-psychotic anxiety, trifluoperazine hcl should not be administered at doses of more than 6 mg per day or for longer than 12 weeks because the use of trifluoperazine hcl at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings ). the effectiveness of trifluoperazine hcl as a treatment for non-psychotic anxiety was established in a four-week clinical multicenter study of outpatients with generalized anxiety disorder (dsm-iii). this evidence does not predict that trifluoperazine hcl will be useful in patients with other non-psychotic conditions in which anxiety, or signs that mimic anxiety, are found (i.e., physical illness, organic mental conditions, agitated depression, character pathologies, etc.). trifluoperazine hcl has not been shown effective in the management of behavioral complications in patients with mental retardation. a known hypersensitivity to phenothiazines, comatose or greatly depressed states due to central nervous system depressants and, in cases of existing blood dyscrasias, bone marrow depression and pre-existing liver damage.

TRIFLUOPERAZINE HYDROCHLORIDE tablet, film coated Spojené státy - angličtina - NLM (National Library of Medicine)

trifluoperazine hydrochloride tablet, film coated

bryant ranch prepack - trifluoperazine hydrochloride (unii: 6p1y2snf5v) (trifluoperazine - unii:214izi85k3) - for the management of schizophrenia. trifluoperazine hcl is effective for the short-term treatment of generalized non-psychotic anxiety. however, trifluoperazine hcl is not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines). when used in the treatment of non-psychotic anxiety, trifluoperazine hcl should not be administered at doses of more than 6 mg per day or for longer than 12 weeks because the use of trifluoperazine hcl at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings ). the effectiveness of trifluoperazine hcl as a treatment for non-psychotic anxiety was established in a four-week clinical multicenter study of outpatients with generalized anxiety disorder (dsm-iii). this evidence does not predict that trifluoperazine hcl will be useful in patients with other non-psychotic conditions in which anxiety, or signs that mimic anxiety, are found (i.e., physical illness, organic mental conditions, agitated depression, character pathologies, etc.). trifluoperazine hcl has not been shown effective in the management of behavioral complications in patients with mental retardation. a known hypersensitivity to phenothiazines, comatose or greatly depressed states due to central nervous system depressants and, in cases of existing blood dyscrasias, bone marrow depression and pre-existing liver damage.

ELICALM 10 F. TAB Indie - angličtina - Central Drugs Standard Control Organization

elicalm 10 f. tab

elite ph. - trifluoperazine hcl.,chlorpromazine hcl.,trihexyphenidyl hcl. - f. tab - 5,50,2;mg - 10

ELICALM 10 SF TAB Indie - angličtina - Central Drugs Standard Control Organization

elicalm 10 sf tab

elite ph. - trifluoperazine hcl.,chlorpromazine hcl.,trihexyphenidyl hcl. - sf tab - 5,25,2;mg - 10

LACALM 10 F. TAB Indie - angličtina - Central Drugs Standard Control Organization

lacalm 10 f. tab

la drug - trifluoperazine hcl.,chlorpromazine hcl.,trihexyphenidyl hcl. - f. tab - 5,50,2;mg - 10

MANCALM 10 F. TAB Indie - angličtina - Central Drugs Standard Control Organization

mancalm 10 f. tab

mano - trifluoperazine hcl.,chlorpromazine hcl.,trihexyphenidyl hcl. - f. tab - 5,50,2;mg - 10

MANOCALM 10 F. TAB Indie - angličtina - Central Drugs Standard Control Organization

manocalm 10 f. tab

orchid hc. - trifluoperazine hcl.,chlorpromazine hcl.,trihexyphenidyl hcl. - f. tab - 5,50,2;mg - 10